Монотерапия капецитабином: эффективное и безопасное лечение метастатического рака молочной железы

1. American Cancer Society. Cancer Facts and Figures 2005. Available at http://www.cancer.org/down loads/STT/CAFF2005f4PWSecured.pdf. Accessed March 23, 2006.
2. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer. Version I. Available at http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed March 23, 2006.
3. Paridaens R, Biganzpli L, Bruning P et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 2000; 18: 724–33.
4. Sledge GW, Neuberg D, Bernardo P et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (EI193). J Clin Oncol 2003; 21: 588–92.
5. Bishop JP, Dewar L Toner GC et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999; 17: 2355–64.
6. Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17: 1413–24.
7. Sjostrom J, Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-fIuorouracil in patients with advanced breast cancer after anthracycline failure: a randomized phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194–201.
8. Bonneterre J, Roche H, Monnier A et al. Docetaxel vs 5-fluorouracil plus vinorelhine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002; 87: 1210–5.
9. Margolin KA, Doroshow JH, Akman SA et al. Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin. J Clin Oncol 992; 10: 1278–83.
10. Doroshow JH, Leong L, Margolin K et al. Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. J Clin Oncol 1989; 7: 439–44.
11. Loprinzi CL, Ingle IN, Schaid DJ et al. 5-Fluorouracil plus leucovorin in women with metastatic breast cancer. A phase II study. Am J Clin Oncol 1991; 14: 30–2.
12. Swain SM, Lippman ME, Egan EF et al. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 890–9.
13. Cameron DA, Gabra H, Leonard RC. Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 1994: 70: 120–4.
14. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274–81.
15. Schuller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 2000: 45: 291–7.
16. Liu G, Franssen E, Fitch MI et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110–5.
17. Borner M, Sehsffski P, de Wit R et al. A randomized crossover trial comparing oral UFT (uracil/tegafur) + leucovorin (LV) and intravenous fluorouracil (PU) + LV for patient preference and pharmacokinetics in advanced colorectal cancer. Proc Am Soc Clin Onco1 2000; 19: 191a.
18. Roche Laboratories Inc. Xeloda (capecitabine) Tablets Prescribing Information. Available at http://www.rocheusa.com/products/xeloda/pi.pdf. Accessed March 23, 2006.
19. Wilson E. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927; 22: 209–12.
20. O'Shaughnessy JA, Blum J, Moiseyenko V et al. Randomized, openlabel, phase II trial of oral capecitabine (Xeloda) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12: 1247–54.
21. Minea L, Stanculeanu DL, Cringeanu A et al. Capecitabine monotherapy for elderly patients with metastatic breast cancer. J Clin Oncol 2004; 22(suppl. 14): 76s.
22. Bajetta E, Procopio G, Celio L et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23: 2155–61.
23. Kalbakis K, Kouroussis C, Kakolyris S et al. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continues infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic brea1t cancer (M BC) pretreated with anthracycline and taxanes. Br J Cancer 2001; 85: 798–02.
24. Lee SH, Lee J, Park J et al. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Med Oncol 2004; 21: 223–1.
25. Kurnianda J, Haryadi A, Arayandono T et al. Efficacy of capecitabine (X) monotherapy in the anthracycline-pretreated metastatic breast cancer (MBC) preliminary results of phase II study (experience in a single institution). Ann Onco1 2004; 15(suppl. 3): iii41.
26. Portela C, Costa N, Pereira D et al. Treatment of metastatic breast cancer with capecitabine-one centre experience. Ann Oncol 2004: 15(suppl. 3): iii48.
27. Pierga JY, Fumoleau P, Brewer Y et al. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program. Breast Cancer Res Treat 2004; 88: 117–29.
28. Zamora P, Alvarez de Mon M, Calvo L et al. Capecitabine (X) in elderly patients with metastatic breast cancer. Ann Oncol 2004; 15(suppl. 3): iii40.
29. Wist Ell., Sommer HH, Ostenstad B et al. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 2004; 43: 186–9.
30. Fumoleau P, Largillier R, Clippe C et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthacycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40: 536–42.
31. Longo P, Magnolfi E, Borgomastro A et al. Capecitabine (X) in elderly patients (pts) with hormone-refractory metastatic breast cancer (MBC). J Clin Oncol 2004; 22(suppl. 14S): 86s.
32. Sezgin VC, Sanli UA, Karabulut B et al. Capecitabine (X I monotherapy in patients (pts) with pretreated metastatic breast cancer (MBC): is response correlated to cerbB-2 expression? J Clin Onco1 2004; 22(suppl. 14): 66.
33. Vaid AK, Gupta S, Doval DC et al. Capecitabine: Single institution experience from North India in metastatic breast cancer. J Clin Oncol 2004; 22(suppl. 14): 80.
34. Reichardt P, Von Minckwitz G, Thuss-Patience PC et al. Multicenter phase II study of oral capecitabine (XelodaR) in patients with metastatic' breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14: 1227–33.
35. Bauer-Kosinka B, Glogowska I, Lemanska I et al. Capecitabine monotherapy in the treatment of patients with chemotherapy pre-treated metastatic breast cancer. Proc Am Soc Clin Oncol 2003: 22: 80.
36. Hillian K, Koeppen H, Tobin P et al. The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003; 22: 191.
37. Chu D, Li W. Capecitabine is effective and very well tolerated in Chinese patients with pretreated advanced or relapsed breast carcinoma. Proc Am Soc Clin Oncol 2003: 22: 60.
38. Soto C, Reyes S, Delgadillo F et al. Capecitabine (X) plus docetaxel (T) versus capecitabine plus paclitaxel (P) versus sequential capecitabine then taxane in anthracycline-pretreated patients with metastatic breast cancer: early results. Proc Am Soc Clin Oncol 2003; 22: 8.
39. Torrecillas L. Cortes P, Tokunaga C et al. Capecitabine monotherapy or combined with taxanes: early results in quality of life in patients with metastatic breast Cancer. Proc Am Soc Clin Oncol 2003; 22: 749.
40. Venturini M, Bell R, Paridaens R et al. Capecitabine monotherapy is active, well tolerated and provides convenient outpatient therapy for patients with taxane-pretreated advanced breast cancer: findings from an expanded access program. Eur J Cancer Suppl. 2003; 1: S137.
41. Bulusu V, Le Vay J, Hockney R et al. Oral capecitabine monotherapy in taxane and anthracycline pretreated metastatic breast cancer (MBC): Suffolk Oncology Centre experience. Eur J Cancer Supp1 2003; 1: S140.
42. Talbot DC, Moiseyenko V, Van Belle S et al. Randomized, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86: 1367–72.
43. Jakob A, Bokemeyer C, Knop S et al. Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation – a phase II study. Anticancer Drugs 2002; 13: 405–10. 
44. Semiglazov T, Gershanovich M, Semiglazov V. Oral capecitabine (Xeloda) in the treatment of anthracycline-refractory, anthracycline and docetaxel-refractory metastatic breast cancer (MBC). Proc Am Soc Clin Onco1 2002; 21: 62b.
45. Nadal J, Viniegara M, O'Connor J et al. Capecitabine is active as oral treatment for metastatic breast cancer (MBC): a single institutional experience. Ann Oncol 2004; 13 (suppl. 5): 68. 
46. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92: 1759–68. 
47. Kusama M, Sano M, Ikeda T et al. A phase II study of Xeloda (capecitabine) in patients with advanced/metastatic breast carcinoma: the Cooperative Study Group of Capecitabine for Breast Carcinoma. Proc Am Soc Clin Oncol 2001; 20: 44b.
48. Watanabe T, Katsumata N, Sasaki Y et al. A multicenter phase II trial of Xeloda (capecitabine) in patients with docetaxel-refractory advanced/metastatic breast cancer. Proc Am Soc Clin Oncol 2001; 20: 61b.
49. Cervantes G, Torrecillas L, Erazo A et al. Capecitabine (XELODA) as treatment after failure to taxanes for metastatic breast cancer. Proc Am Soc Clin Onco1 2000; 19: 121a.
50. Wong Z, Wong K, Chew L et al. Capecitabine as an oral chemotherapeutic agent in the treatment of refractory metastatic breast carcinoma (MBC). Proc Am Soc Clin Onco1 2000; 19: 120a.
51. Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485–93.
52. Vcrma S, Clemons M, Dranitsaris G et al. Survival differences observed in anthracycline and taxane refractory metastatic breast cancer patients treated with capecitabine when compared with vinorelbine. Available at http: //www.sabcs.org/SymposiurnOnline/index. asp#abstracts. Accessed March 23, 2006.
53. Ross JS, Fletcher JA, Linette GP et al. The HER–2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. The Oncologist 2003; 8: 307–25.
54. Largiller R, Etienne MC, Morlot P et al. Prospective analysis of dihydropyrimidine dehydrogenase (DPD) activity predicting capecitabinerelated toxicities in metastatic breast cancer patients. Proc Am Soc Clin Oncol 2004; 22: 134.
55. Sudaram S, Lancaster D, Silva J et al. Oral capecitabine is an active and well tolerated primary palliative treatment in palliative with metastatic breast cancer who progress after high dose chemotherapy and autologous stem cell support. Proc Am Soc Clin Oncol 2000; 19; 58a.
56. Segalla JGM, Oliveira CT, Lago S et al. Effect of capecitabine (X) on quality of life (QoL) in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2004; 22(suppl. 14): 76Is.
57. Segalla G, Oliveira C, Lago S et al. Quality of Life (QoL) in patients with metastatic breast cancer (MBC) treated with capecitabine (Xeloda). Eur J Cancer Suppl. 2003; 1: S136.
58. Beato CAM, Federico MH, Van Eyll B et al. Effects of capecitabine (X) on quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol 2004; 22(suppl. 14): 758s.
59. Lago S. Quality of life (QoL) in patients with metastatic breast cancer (MBC) taking Xeloda (capecitabine). Proc Am Soc Clin Oncol 2003; 22: 745.
60. Segalla J, Oliveira C, Cabral S et al. Capecitabine (X) improves quality of life (QoL) in patients (pts) with metastatic breast cancer (MBC). Available at http://www.sabcs.org/symposiumOnline/index.asp#abstracts. Accessed March 23, 2006.
61. Segalla JM, Oliveira CT, Lago S et al. Quality of life (QoL) improvements in patients (pts) with metastatic breast cancer (MBC) treated with capecitabine (X). Ann Oncol 2004; 15(suppl. 3): 170.
62. Baran R, Dupere W, Susan M et al. Clinical and economic outcomes associated with metastatic breast cancer in managed care populations: capecitabine (Xeloda) versus comparison therapies. Proc Am Soc Clin Oncol 2002; 21: 33b.
63. Kimishima I, Tominaga T, Hiroki K et al. Randomized controlled trial comparing oral doxifIuridine (an intermediate metabolite of capecitabine) plus oral cyclophosphamide with doxifluridine in node positive breast cancer patients after curative resection. Proc Am Soc Clin Onco1 2002; 21: 47a.
64. Xu B, Tian L, Wu Q et al. Capecitabine (X) combined with vinorelbine (V) in Chinese patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2004; 22(suppl. 14): 62s.
65. Clemons MJ, Verma S, Leung V et al. Palliative chemotherapy with vinorelbine or capecitabine in women with anthracycline and taxane refractory metastatic breast cancer: J Clin Oncol 2004; 2(suppl. 14): 70s.
66. Estevez LG, Batista N, Sanchez-Rovira P et al. Phase II study with the combination of capecitabine (C) and vinorelbine (V) in metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. J Clin Oncol 2004; 22(suppl. 14): 63s.
67. Gligorv J, Beerblock K, Selle F et al. Capecitabine and oral vinorelbine in metastatic breast cancer: preliminary experience. Proc Am Soc Clin Oncol 2003; 22: 88.
68. Ghosn M, ChahineG., Kattan J et al. Phase II study of sequential administration of vinorelbine capecitabine combination followed by weekly docetaxel as first line chemotherapy for advanced breast cancer. J Clin Onco1 2004; 22 (14S): 80s.
69. Ahn JH, Kim SB, Kim TW et al. Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci 2004; 19: 547–53.
70. Stuart N, Bishop JL, Johnson SRD et al. Vinorelbine and capecitabine (VX) for advanced breast cancer: a phase II study showing good activity and potential for further development. Proc Am Soc Clin Oncol 2003; 22: 46.
71. Llorca C, Mayordomo E, Ardrover I et al. Activity and safety of biweekly docetaxel plus capecitabine as first–line treatment for patients with metastatic breast cancer. J Clin Oncol 2004; 22(suppl. 14): 73s.
72. Chun JH, Lee HG, Lee ES et al. Frontline docetaxel (T)/capecitabine (X) combination therapy in patients (pts) with metastatic breast cancer (MBC): a phase II study. J Clin Oncol 2004; 22(suppl. 14): 7Is.
73. Bellet M, Munoz M, Pelegri A et al. Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage). J Clin Oncol 2004; 22(suppl. 14): 64s.
74. Soto C, Reyes S, Delgadillo F et al. Capecitabine (X) plus docetaxel (T) vs capecitabine plus paclitaxel (P) vs sequential capecitabine then taxane in anthracycline pretreated patients (pts) with metastatic breast cancer: early results. Proc Am Soc Clin Oncol 2003; 22: 8.
75. Malfair-Taylor S, Verma S, Barnett J et al. Cost-effective analysis of capecitabine and docetaxel (DC) versus taxanes alone in the treatment of anthracycline resistant metastatic breast cancer (MBC): perspectives from two Canadian provinces. Proc Am Soc Clin Oncol 2003; 22: 558.
76. Mackey JR, Tonkin K, Scarfe AG et al. Final results of a phase II clinical trial of weekly docetaxel (T) in combination with capecitabine (X) in anthracycline pretreated metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003; 22: 42.
77. Ramaswamy B, Rhoades CA, Kendra KL et al. Phase II trial of weekly docetaxel (D) and prolonged capecitabine (C) in metastatic breast cancer (MBC) patients (pts). Proc Am Soc Clin Oncol 2003; 22: 59.
78. Andres R, Mayordomo J, Isla D et al. Capecitabine p1us gemcitabine is an active combination for patients with metastatic breast cancer refractory to anthracyclines and taxanes. Proc Am Sos Clin Oncol 2003; 22: 89.
79. Manga G, Lopez-Criado P, Mendez M et al. Gemcitabine (G) plus capecitabine (C) in previously treated metastatic breast cancer (MBC) patients: results from a phase II GOTI trial. Proc Am Soc Clin Oncol 2003; 22: 66.
80. Venturini M, Catzeddu T, Del Mastro L et al. Erlotinib given sequentially to capecitabine and vinorelbine as first-second chemotherapy in metastatic breast cancer patients: a dose finding study. J Clin Oncol 2004; 22(suppl. 14): 84s.
81. Gebbia N, Fulfaro F, Badalamenti G et al. A phase 2 study of oxaliplatin (O) – capecitabine (C) chemotherapy in metastatic breast cancer (MBC) patients pretreated with anthracyclines and taxanes. J Clin Oncol 2004; 22(suppl. 14): 53s.
82. Biganzoli L, Aapro M. Elderly breast cancer patients: adjuvant chemotherapy and adjuvant endocrine therapy. Gynakol Geburlshilfliche Rundsch 2005; 45: 137–42.
83. Yamamoto T, Iwase S, Kitamura K et al. Multicenter phase II study of trastuzumab (H) and capecitabine (X) as first- or second-line treatment in HER2 over-expressing metastatic breast cancer (Japan Breast Cancer Study Group: JBCSG–003). J Clin Oncol 2005; 23: 78s.
84. Schaller G, Bangemann N, Weber J et al. Efficacy and safety of trastunzumab plus capecitabine in a German multicentre phase II study of pretreated metastatic breast cancer. J. Clin Oncol 2005; 23: 57s.